EZH2 and hematologic disorder: Although existing EZH2 inhibitors, like tazemetostat, show limited efficacy in certain hematological malignancies, and inhibitors like JQ1 effectively target HOTAIR transcription, the complexity of epigenetic regulation underscores the limitations of single-drug therapies, including off-target effects and global impacts.